Likewise, SCFAs have shown promising results in the modulation of CMD, as they can improve different risk factors associated to these diseases, such as dyslipidemia, cholesterol, insulin resistance, hyperglycemia, and inflammation, thanks mainly to their capability to inhibit HDAC and activate the different FFAR receptors. Here, HDAC9 is linked to Insulin resistance.